Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.
On April 14, 2026, bioAffinity Technologies reported a clinical case in which its CyPath® Lung sputum test helped guide management of a 70-year-old high-risk patient whose imaging and risk models suggested a 30-millimeter nodule was likely malignant. Despite PET scans and established lung cancer risk calculators indicating high cancer probability and a biopsy being scheduled, the CyPath® Lung result of “Unlikely Malignancy” prompted the treating pulmonologist to order another CT scan before proceeding.
The follow-up imaging showed the nodule had completely resolved, supporting the physician’s suspicion that the lesion reflected a reversible inflammatory process rather than lung cancer and sparing the patient a risky, costly and unnecessary biopsy. The company highlighted this single-patient case as evidence that adding CyPath® Lung to diagnostic pathways for indeterminate pulmonary nodules may help clinicians defer invasive procedures in complex, high-risk patients, while cautioning that the example does not by itself establish generalized clinical utility for the test.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held back primarily by weak financial performance—widening losses and accelerating cash burn—despite some balance-sheet improvement. Offsetting this, technical indicators show constructive momentum, and corporate updates point to improving product adoption and clinical validation progress, but valuation remains constrained by ongoing losses and no dividend.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its first product, CyPath® Lung, is a sputum-based test marketed as a CLIA-overseen Laboratory Developed Test by subsidiary Precision Pathology Laboratory Services, targeting high-risk patients undergoing lung cancer screening.
CyPath® Lung uses advanced flow cytometry, proprietary artificial intelligence and a fluorescent porphyrin preferentially taken up by cancer and cancer-related cells to identify malignant cell populations in sputum. In clinical trials involving high-risk patients with small indeterminate nodules under 20 millimeters, the test demonstrated 92% sensitivity, 87% specificity and 88% overall accuracy, and is intended to be used alongside other clinical findings rather than as a stand-alone diagnostic tool.
Average Trading Volume: 8,884,404
Technical Sentiment Signal: Sell
Current Market Cap: $15.07M
For detailed information about BIAF stock, go to TipRanks’ Stock Analysis page.